12:00 AM
Nov 08, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy

National Cancer Institute researchers presented data from 63 androgen independent prostate cancer patients in which 53 and 68 percent of low and...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >